Keller Postman LLC Associate Ashley Barriere has been appointed to the Plaintiffs’ Steering Committee and will lead the Law & Briefing committee for the Onglyza and Kombiglyze XR Products Liability Litigation MDL. Judge Karen K. Caldwell in the U.S. District Court for the Eastern District of Kentucky ordered Barriere’s appointment today.
In the lawsuits, which were consolidated into an MDL in 2018, individuals who took Onglyza (saxagliptin) and Kombiglyze XR (saxagliptin and metformin) to treat Type 2 diabetes allege that the drugs caused serious cardiac complications. Defendants Bristol-Myers Squibb and AstraZeneca began selling the drugs in 2009 and 2010, before completing a cardiac risk study recommended by the U.S. Food and Drug Administration.
“I’m honored to represent the plaintiffs in this MDL, to seek justice for those injured, and to lead the law and briefing effort,” Barriere said. “So much of a complex lawsuit is won and lost in the law and briefing stages, and our team at Keller Postman recognizes that.”
Barriere’s appointment reinforces Keller Postman’s reputation as a leader in complex litigation for plaintiffs, including in multidistrict litigations throughout the United States. Keller Postman Partner Ashley Keller chairs the Law & Briefing Committee in the Zantac (Ranitidine) Products Liability MDL, and Partner Nicole Berg sits on the Law & Briefing Subcommittee in the 3M Combat Arms Earplug Products Liability MDL.
– – –
*As of April 2022, the firm has changed its name from Keller Lenkner to Keller Postman.
We're ready to start fighting for you. Tell us more about your situation and a member of our team will contact you soon.
First Name
Last Name
Email Address
Phone Number
Zip Code
—Please choose an option—Acetaminophen (Tylenol)OxbrytaCamp LejeuneDepo-ProveraHair RelaxerNEC/Infant-FormulaParagardTalcum Powder3MZantacAuto Accident InjurySlip and FallAnimal Injury/AttackWork Place InjuryMedical Professional InjuryOther
Describe Your Issue
By submitting, you agree to our Terms & Privacy Policy, and you are providing express consent to receive automated communications including calls, texts, emails, and/or prerecorded messages.